Kimyrsa is a drug owned by Melinta Therapeutics Llc. It is protected by 3 US drug patents filed in 2021 out of which none have expired yet. Kimyrsa's patents have been open to challenges since 07 August, 2023. Based on its patents and exclusivities, its generic launch date is estimated to be Jul 16, 2035. Details of Kimyrsa's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents protect the active ingredient(API) of the drug. Only drug patent owner can launch products that use this active ingredient until these patents expire. | |||
| US9649352 | High purity oritavancin and method of producing same |
Jul, 2035
(10 years from now) | Active |
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US9682061 | Methods of treating bacterial infections using oritavancin |
Apr, 2030
(5 years from now) | Active |
| US8420592 | Methods of treatment using single doses of oritavancin |
Aug, 2029
(4 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Kimyrsa's patents.
Latest Legal Activities on Kimyrsa's Patents
Given below is the list of recent legal activities going on the following patents of Kimyrsa.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Year, Large Entity | 28 Sep, 2020 | US9649352 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 28 Sep, 2020 | US9682061 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 15 Sep, 2020 | US8420592 |
| Recordation of Patent Grant Mailed Critical | 20 Jun, 2017 | US9682061 |
| Patent Issue Date Used in PTA Calculation Critical | 20 Jun, 2017 | US9682061 |
| Email Notification Critical | 01 Jun, 2017 | US9682061 |
| Issue Notification Mailed Critical | 31 May, 2017 | US9682061 |
| Patent Issue Date Used in PTA Calculation Critical | 16 May, 2017 | US9649352 |
| Dispatch to FDC | 16 May, 2017 | US9682061 |
| Recordation of Patent Grant Mailed Critical | 16 May, 2017 | US9649352 |
FDA has granted several exclusivities to Kimyrsa. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Kimyrsa, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Kimyrsa.
Exclusivity Information
Kimyrsa holds 3 exclusivities. All of its exclusivities have expired in 2024. Details of Kimyrsa's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 06, 2019 |
| New Product(NP) | Mar 12, 2024 |
| Generating Antibiotic Incentives Now(GAIN) | Aug 06, 2024 |
Several oppositions have been filed on Kimyrsa's European patents. EP oppositions can significantly impact the timeline for the generic launch of drugs. If an opposition results in the revocation or amendment of a patent, it can shorten the exclusivity period of the original drug. This can lead to an earlier entry of generic versions into the market. To help you estimate the potential early arrival of Kimyrsa's generic, the next section provides detailed information on ongoing and past EP oppositions related to Kimyrsa patents.
Kimyrsa's Oppositions Filed in EPO
Kimyrsa has faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Jan 13, 2017, by Prüfer & Partner Mbb. This opposition was filed on patent number EP09810708A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
 | |||
| EP09810708A | Jan, 2017 | Prüfer & Partner mbB | Granted and Under Opposition |
US patents provide insights into the exclusivity only within the United States, but Kimyrsa is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Kimyrsa's family patents as well as insights into ongoing legal events on those patents.
Kimyrsa's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Kimyrsa's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Jul 16, 2035 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Kimyrsa Generics:
There are no approved generic versions for Kimyrsa as of now.
Alternative Brands for Kimyrsa
Kimyrsa which is used for treating acute bacterial skin and skin structure infections with a single dose of 1200mg of oritavancin or its equivalent., has several other brand drugs using the same active ingredient (Oritavancin Diphosphate). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |
|---|---|---|
| Melinta Therap |
|
About Kimyrsa
Kimyrsa is a drug owned by Melinta Therapeutics Llc. It is used for treating acute bacterial skin and skin structure infections with a single dose of 1200mg of oritavancin or its equivalent. Kimyrsa uses Oritavancin Diphosphate as an active ingredient. Kimyrsa was launched by Melinta Therap in 2021.
Approval Date:
Kimyrsa was approved by FDA for market use on 12 March, 2021.
NCE-1 date:
NCE-1 date also known as the four year date occurs four years after the original drug approval and marks the first opportunity for a generic manufacturer to file an ANDA with a Paragraph IV certification. This is the earliest point when generic competition might begin, provided the challenge is successful. Since the approval date for Kimyrsa is 12 March, 2021, its NCE-1 date is estimated to be 07 August, 2023.
Active Ingredient:
Kimyrsa uses Oritavancin Diphosphate as the active ingredient. Check out other Drugs and Companies using Oritavancin Diphosphate ingredient
Treatment:
Kimyrsa is used for treating acute bacterial skin and skin structure infections with a single dose of 1200mg of oritavancin or its equivalent.
Dosage:
Kimyrsa is available in powder form for intravenous use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| EQ 1.2GM BASE/VIAL | POWDER | Prescription | INTRAVENOUS |